QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
NASDAQ:ALLK

Allakos - ALLK Stock Forecast, Price & News

$7.57
+0.17 (+2.30%)
(As of 02/2/2023 04:29 PM ET)
Add
Compare
Today's Range
$7.39
$7.73
50-Day Range
$6.95
$8.42
52-Week Range
$2.54
$8.73
Volume
694,538 shs
Average Volume
765,534 shs
Market Capitalization
$644.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

Allakos MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
38.7% Upside
$10.50 Price Target
Short Interest
Healthy
6.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.86
Upright™ Environmental Score
News Sentiment
0.77mentions of Allakos in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.27) to ($2.29) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.67 out of 5 stars

Medical Sector

75th out of 1,030 stocks

Pharmaceutical Preparations Industry

26th out of 502 stocks


ALLK stock logo

About Allakos (NASDAQ:ALLK) Stock

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.

Receive ALLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

ALLK Stock News Headlines

Allakos Inc. (NASDAQ:ALLK) Sees Large Decrease in Short Interest
Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
Why Is Allakos (ALLK) Stock Soaring 25% Today?
See More Headlines
Receive ALLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

ALLK Company Calendar

Last Earnings
11/07/2022
Today
2/02/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALLK
Fax
N/A
Employees
192
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.50
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+38.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$-269,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.20 per share

Miscellaneous

Free Float
56,874,000
Market Cap
$644.96 million
Optionable
Not Optionable
Beta
0.46

Key Executives

  • Robert AlexanderRobert Alexander
    Chief Executive Officer & Director
  • Adam L. Tomasi
    President & Chief Operating Officer
  • Harlan Baird Radford
    Chief Financial Officer
  • Craig Paterson
    Chief Medical Officer
  • Ruby Casareno
    Vice President-Technical Operations













ALLK Stock - Frequently Asked Questions

Should I buy or sell Allakos stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALLK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLK, but not buy additional shares or sell existing shares.
View ALLK analyst ratings
or view top-rated stocks.

What is Allakos' stock price forecast for 2023?

4 brokerages have issued 12-month target prices for Allakos' shares. Their ALLK share price forecasts range from $8.00 to $13.00. On average, they expect the company's stock price to reach $10.50 in the next year. This suggests a possible upside of 40.2% from the stock's current price.
View analysts price targets for ALLK
or view top-rated stocks among Wall Street analysts.

How have ALLK shares performed in 2023?

Allakos' stock was trading at $8.42 at the beginning of the year. Since then, ALLK stock has decreased by 11.0% and is now trading at $7.49.
View the best growth stocks for 2023 here
.

Are investors shorting Allakos?

Allakos saw a drop in short interest during the month of January. As of January 15th, there was short interest totaling 2,810,000 shares, a drop of 5.7% from the December 31st total of 2,980,000 shares. Based on an average daily trading volume, of 1,070,000 shares, the short-interest ratio is presently 2.6 days. Currently, 6.0% of the company's shares are sold short.
View Allakos' Short Interest
.

When is Allakos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our ALLK earnings forecast
.

How were Allakos' earnings last quarter?

Allakos Inc. (NASDAQ:ALLK) released its earnings results on Monday, November, 7th. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.25.

What other stocks do shareholders of Allakos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS).

When did Allakos IPO?

(ALLK) raised $96 million in an initial public offering on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.

What is Allakos' stock symbol?

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Who are Allakos' major shareholders?

Allakos' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Bank of Montreal Can (0.14%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adam Tomasi, Daniel Janney, Guy P Nohra, Henrik S Md Rasmussen, John P Mckearn, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More and Steven P James.
View institutional ownership trends
.

How do I buy shares of Allakos?

Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allakos' stock price today?

One share of ALLK stock can currently be purchased for approximately $7.49.

How much money does Allakos make?

Allakos (NASDAQ:ALLK) has a market capitalization of $638.15 million. The company earns $-269,860,000.00 in net income (profit) each year or ($6.76) on an earnings per share basis.

How many employees does Allakos have?

The company employs 192 workers across the globe.

How can I contact Allakos?

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The official website for the company is www.allakos.com. The company can be reached via phone at (650) 597-5002 or via email at ir@allakos.com.

This page (NASDAQ:ALLK) was last updated on 2/2/2023 by MarketBeat.com Staff